Amplimed Corporation
529-1000
www.amplimed.com

AmpliMed® Corporation, a clinical-stage pharmaceutical company founded by world-renowned oncologists, has a lead compound, Amplimexon®, in Phase II clinical trials, with early evidence of efficacy and low levels of toxicity. The Company also has two other promising drug candidates, benzimate, which entered Phase I clinical study during 2006, and Amplizone™, which is scheduled to begin Phase I studies in 2007. The Company is focused on the development of small-molecule oncology drugs with novel mechanisms of action.

The Critical Path Institute
547-3440
www.c-path.org

The Critical Path Institute, a non-profit, publicly funded organization, serves as “neutral ground” to bring together scientists from the Food and Drug Administration (FDA), academia, and the pharmaceutical industry to accelerate the development of safe new therapies.

Systems Medicine Inc.
www.systems-medicine.com

Systems Medicine, Inc. (“SMi”, “the Company”) develops oncology products by integrating predictive cellular pharmacogenomics (“omics”) with world-class clinical and regulatory expertise. This allows SMi to develop patient-selective therapies by defining the “context-of-vulnerability” of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. The Company’s business plan is to acquire pre-clinical products, assess the context-of-vulnerability for those drugs, and optimally position those drugs for success in clinical development and commercial use.

Vision NOW
299-4100
www.optometrists.org/visionnow

At Vision NOW, our passion has inspired us to create a "state of the art" Vision Therapy program that integrates the best of what Developmental Optometry, Naturopathic Medicine and Neuro-Optometric Rehabilitation have to offer. We specialize in helping children with learning issues at school.